Imidazopyrimidines, potent inhibitors of p38 MAP kinase

  • Bioorg Med Chem Lett. 2003 Feb 10;13(3):347-50. doi: 10.1016/s0960-894x(02)01020-x.
Kenneth C Rupert  1 ,  James R Henry ,  John H Dodd ,  Scott A Wadsworth ,  Druie E Cavender ,  Gilbert C Olini ,  Bohumila Fahmy ,  John J Siekierka
Affiliations
  • 1. Drug Discovery, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 1000 Route 202, Raritan, NJ 08869, USA. [email protected]
PMID: 12565927 DOI: 10.1016/s0960-894x(02)01020-x
Abstract

The MAP kinase p38 is implicated in the release of the pro-inflammatory cytokines TNF-alpha and IL-1 beta. Inhibition of cytokine release may be a useful treatment for inflammatory conditions such as rheumatoid arthritis and Crohn's disease. A novel series of imidazopyrimidines have been discovered that potently inhibit p38 and suppress the production of TNF-alpha in vivo.

Products